RxDoctor Payments Data

David Durussel, MD

Pain Medicine · El Paso, TXNPI 1700896982

Payments from drug & device makers

$19,406in general payments, 2019–2025

Across 381 payments — averaging $50.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • Scilex Pharmaceuticals Inc.$208
  • AbbVie$157
  • Medtronic$101
  • Johnson & Johnson$45
  • Amgen$32
  • plus $56 from 3 others

What the payments were for

  • Consulting fees$8,98346%
  • Travel & lodging$5573%
  • Food & beverage$9,86751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott352$18,807
Scilex Pharmaceuticals Inc.12$208
AbbVie(2 entities)8$157
Medtronic(2 entities)2$101
Johnson & Johnson2$45
Amgen(2 entities)2$32
Vertex1$25
Fidia Pharma USA Inc.1$17
GRT US Holding, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,406 in reported general payments places this provider in the 85th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$268,381
Medicare patients
389
Services billed
10,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina39$41,829
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,339$31,810
EliquisApixaban14$7,849
Duloxetine Hcl262$5,120
Buprenorphine17$4,086
Pregabalin171$3,742
Naloxone Hcl68$3,685
Celecoxib140$3,454
Acetaminophen-CodeineAcetaminophen With Codeine195$2,992
Lidocaine38$2,987
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen110$2,876
Diclofenac Sodium24$1,869
Gabapentin159$1,631
Clindamycin Hcl103$1,381
Tizanidine Hcl114$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$157$41,82939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 pain medicine providers in Texas.

Other pain medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →